Artwork
iconShare
 
Manage episode 442317268 series 2715815
Content provided by Haydn Brain & Ed Gotham, Haydn Brain, and Ed Gotham. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Haydn Brain & Ed Gotham, Haydn Brain, and Ed Gotham or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Marc Stapley, CEO at Veracyte, joins OPTO Sessions to discuss the company’s use of AI and machine learning, its strategic focus on the cancer diagnostics cycle, and how its acquisition of MRD platform C2i expands this focus to the post-treatment phase. Enjoy!

-----
The content in this podcast is for informational purposes only. Opto Markets LLC does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing. The information provided is not an endorsement of this product and is for information and/or educational purposes only.

  continue reading

255 episodes